{"filing":{"accession_number":"0001213900-26-088705","cik":"0001949257","ticker":"RDPTF","company_name":"Radiopharm Theranostics Ltd","form":"6-K","filing_date":"2026-08-13","report_date":"2026-08-13","primary_document":"ea0301905-6k_radiopharm.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1949257/000121390026088705/ea0301905-6k_radiopharm.htm"},"events":[{"id":27525,"run_id":25095,"accession_number":"0001213900-26-088705","anchor_item_number":"EX-99.1","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.92,"summary":"This is a Notice of Extraordinary General Meeting and proxy form for shareholder approval of multiple equity issuances totaling approximately $18.5 million, including placement shares, ADS shares, options, and warrants. While the document is primarily a governance/procedural notice, the underlying resolutions seek shareholder approval for material dilutive equity issuances (408.8M first-tranche placement shares, 384.5M ADS shares, 40M second-tranche shares, 448.8M placement options, 666.7M SPP shares and options, 200M shortfall options, 1.3M ADR warrants, and director/CEO equity grants). The aggregate capital raise of ~$18.5M and substantial share dilution would materially affect investor assessment. This is classified as governance_other rather than dilutive_issuance because the exhibit is the notice and proxy materials for the shareholder meeting itself, not a discrete announcement of the issuance; the actual issuances are contingent on shareholder approval at the meeting.","company_name":"Radiopharm Theranostics Ltd","ticker":"RDPTF","filing_date":"2026-08-13","form":"6-K","submitted_at":null,"items":[{"id":29104,"accession_number":"0001213900-26-088705","item_number":"EX-99.1","item_title":"ea030190501ex99-1.htm","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"This is a Notice of Extraordinary General Meeting and proxy form for shareholder approval of multiple equity issuances totaling approximately $18.5 million, including placement shares, ADS shares, options, and warrants. While the document is primarily a governance/procedural notice, the underlying resolutions seek shareholder approval for material dilutive equity issuances (408.8M first-tranche placement shares, 384.5M ADS shares, 40M second-tranche shares, 448.8M placement options, 666.7M SPP shares and options, 200M shortfall options, 1.3M ADR warrants, and director/CEO equity grants). The aggregate capital raise of ~$18.5M and substantial share dilution would materially affect investor assessment. This is classified as governance_other rather than dilutive_issuance because the exhibit is the notice and proxy materials for the shareholder meeting itself, not a discrete announcement of the issuance; the actual issuances are contingent on shareholder approval at the meeting.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-13T12:02:40.150841+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29104,"accession_number":"0001213900-26-088705","item_number":"EX-99.1","item_title":"ea030190501ex99-1.htm","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"This is a Notice of Extraordinary General Meeting and proxy form for shareholder approval of multiple equity issuances totaling approximately $18.5 million, including placement shares, ADS shares, options, and warrants. While the document is primarily a governance/procedural notice, the underlying resolutions seek shareholder approval for material dilutive equity issuances (408.8M first-tranche placement shares, 384.5M ADS shares, 40M second-tranche shares, 448.8M placement options, 666.7M SPP shares and options, 200M shortfall options, 1.3M ADR warrants, and director/CEO equity grants). The aggregate capital raise of ~$18.5M and substantial share dilution would materially affect investor assessment. This is classified as governance_other rather than dilutive_issuance because the exhibit is the notice and proxy materials for the shareholder meeting itself, not a discrete announcement of the issuance; the actual issuances are contingent on shareholder approval at the meeting.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-13T12:02:40.150841+00:00","company_name":"Radiopharm Theranostics Ltd","ticker":"RDPTF","filing_date":"2026-08-13"}]}